Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP875053.RAtwHaQyOsv72qyNqG-QpoJWAPrfMhgKNqOQjsie7lwbM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP875053.RAtwHaQyOsv72qyNqG-QpoJWAPrfMhgKNqOQjsie7lwbM130_assertion type Assertion NP875053.RAtwHaQyOsv72qyNqG-QpoJWAPrfMhgKNqOQjsie7lwbM130_head.
- NP875053.RAtwHaQyOsv72qyNqG-QpoJWAPrfMhgKNqOQjsie7lwbM130_assertion description "[We also show that VAAST 2.0 outperforms KBAC, WSS, SKAT, and variable threshold (VT) using published case-control datasets for Crohn disease (NOD2), hypertriglyceridemia (LPL), and breast cancer (CHEK2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP875053.RAtwHaQyOsv72qyNqG-QpoJWAPrfMhgKNqOQjsie7lwbM130_provenance.
- NP875053.RAtwHaQyOsv72qyNqG-QpoJWAPrfMhgKNqOQjsie7lwbM130_assertion evidence source_evidence_literature NP875053.RAtwHaQyOsv72qyNqG-QpoJWAPrfMhgKNqOQjsie7lwbM130_provenance.
- NP875053.RAtwHaQyOsv72qyNqG-QpoJWAPrfMhgKNqOQjsie7lwbM130_assertion SIO_000772 23836555 NP875053.RAtwHaQyOsv72qyNqG-QpoJWAPrfMhgKNqOQjsie7lwbM130_provenance.
- NP875053.RAtwHaQyOsv72qyNqG-QpoJWAPrfMhgKNqOQjsie7lwbM130_assertion wasDerivedFrom befree-20150227 NP875053.RAtwHaQyOsv72qyNqG-QpoJWAPrfMhgKNqOQjsie7lwbM130_provenance.
- NP875053.RAtwHaQyOsv72qyNqG-QpoJWAPrfMhgKNqOQjsie7lwbM130_assertion wasGeneratedBy ECO_0000203 NP875053.RAtwHaQyOsv72qyNqG-QpoJWAPrfMhgKNqOQjsie7lwbM130_provenance.